Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1, 2011, Pages 117-123

  Almog, Shlomo ^a,c   Kurnik, Daniel ^a,c   Shimoni, Avichai ^b,c   Loebstein, Ronen ^a,c   Hassoun, Eyal ^a   Gopher, Asher ^a   Halkin, Hillel ^a,c   Nagler, Arnon ^b,c  

^a Institute of Clinical Pharmacology and Toxicology   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bone marrow transplantation; Clearance; Conditioning regimen; Fludarabine; Oxidative stress

Indexed keywords

BUSULFAN; FLUDARABINE; GLUTATHIONE; DRUG DERIVATIVE; MYELOABLATIVE AGENT; VIDARABINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; COMPARATIVE EFFECTIVENESS; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; DRUG STABILITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; REDUCED INTENSITY CONDITIONING; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG INTERACTION; METABOLISM; METHODOLOGY; MIDDLE AGED; PERSONALIZED MEDICINE; PHARMACOKINETICS; REPRODUCIBILITY;

ADULT; AGED; BUSULFAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; GLUTATHIONE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PHARMACOKINETICS; REPRODUCIBILITY OF RESULTS; VIDARABINE; YOUNG ADULT;

EID: 79956198240     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.06.017     Document Type: Article

References (24)

1. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:523-536.
2. McCune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol. 2009;5: 957-969.
3. Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006;20:322-328.
4. Lee JH, Choi SJ, Lee JH, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol. 2005;84:321-330.
5. Aggarwal C, Gupta S, VaughanWP, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stemcell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant. 2006;12:770-777.
6. Dean RM, Pohlman B, Sweetenham JW, et al. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br J Haematol. 2010; 148:226-234.
7. Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des. 2008;14:1936-1949.
8. DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology. 2000;60:143-154.
9. Hassan Z, Hellström-Lindberg E, Alsadi S, et al. The effect of modulation of glutathione cellular content on busulfan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. Bone Marrow Transplant. 2002;30:141-147.
10. Jones RJ, Lee KS, Beschorner WE, et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778-783.
11. Lai WK, Pang CP, Law LK, et al. Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin Chem. 1998;44:2506-2510.
12. Stempak D, Dallas S, Klein J, et al. Glutathione stability in whole blood: effects of various deproteinizing acids. Ther Drug Monit. 2001;23:542-549.
13. Rowland M, Tozer TN. Clinical Pharmacokinetics. 3rd ed. Media, PA: Williams & Wilkins; 1995:98, fig 7-9.
14. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8: 468-476.
15. Madden T, de Lima M, Thapar N, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant. 2007;13:56-64.
16. Geddes M, Kangarloo SB, Naveed F, et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant. 2008;14:220-228.
17. Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004; 104:1574-1577.
18. Johnson L, Orchard PJ, Baker KS. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol. 2008; 48:1052-1062.
19. Bouligand J, Deroussent A, Simonnard N, et al. Induction of glutathione synthesis explains pharmacodynamics of high-dose busulfan in mice and highlights putative mechanisms of drug interaction. Drug Metab Dispos. 2007;35:306-314.
20. Jonas CR, Puckett AB, Jones DP. Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr. 2000;72:181-189.
21. Lu SC. Regulation of glutathione synthesis. Mol Aspects Med. 2009;30:42-59.
22. Sjoo F, Aschan J, Barkholt L, et al. N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogenic stem cell transplantation. Bone Marrow Transplant. 2003;32:349-354.
23. Ballatori N, Krance SM, Marchan R, et al. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Mol Aspects Med. 2009;30:13-28.
24. Adams JD Jr., Lauterburg BH, Mitchell JR. Plasma glutathione and glutathione disulfide in the rat: regulation and response to oxidative stress. J Pharmacol Exp Ther. 1983;227:749-754.